Navigation Links
The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia
Date:6/10/2008

WHITE PLAINS, N.Y., June 10 /PRNewswire/ -- Provid Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society (LLS) today jointly announced the execution of a research agreement to advance the development of a treatment for acute myelogenous leukemia.

Under the arrangement, LLS has contracted with Provid to supply expert medicinal chemistry services in support of an LLS-funded Specialized Center of Research (SCOR) grant at the University of Virginia under the direction of Prof. John Bushweller, Ph.D.

"Provid's expertise adds a critical component to our SCOR program that will help advance our efforts from 'interesting laboratory results' to potential therapies," said Dr. Bushweller.

Louis J. DeGennaro, Ph.D., Chief Scientific Officer of LLS, added, "Our partnership with Provid is the result of a detailed selection process to identify companies that have significant drug discovery experience and fills a critical need for medicinal chemistry expertise. We believe that working with Provid will advance our research programs and speed effective therapies to our patients."

"As a company that applies medicinal chemistry expertise to transform biological discoveries into valuable drug leads, we are enthusiastic to work closely with LLS and Dr. Bushweller in the field of blood cancers," said Dr. Gary Olson, Chief Executive Officer of Provid. "We will dedicate our experienced team to this project to accelerate the validation and translation of research results from the Bushweller lab into potential leads for drug development."

The Provid partnership marks the first project of the Academic Concierge Division announced under LLS's Therapy Acceleration Program (TAP). This innovative program is designed to leverage current academic research investments by providing investigators access to the same expertise and services that pharmaceutical companies utilize. The ultimate goal of all TAP contracts is to advance therapies for patients sufferi
'/>"/>

SOURCE The Leukemia & Lymphoma Society
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
3. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
6. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
7. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
8. Cephalon Receives FDA Approval for TREANDA, a Novel Chemotherapy for Chronic Lymphocytic Leukemia
9. Genta Submits NDA Amendment to FDA for Genasense as Treatment of Chronic Lymphocytic Leukemia
10. Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Hodgkins Lymphoma
11. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... 24, 2014 -- A novel combination of microscopy and ... Energy,s Oak Ridge National Laboratory an unprecedented look at ... physical and electrochemical properties. , The research team ... the surface of a perovskite manganite, a complex material ... avenue to understand surface behavior could benefit researchers who ...
(Date:7/24/2014)... 24, 2014 Gain recognition for ... Chain of the biotech industry. Nominations are now ... brought to you by the Bio Supply ... supply chain management professionals for the past 7 ... of the Biotech industry – Manufacturers, Service Providers, ...
(Date:7/24/2014)... , July 24, 2014  Now available is ... home. Rehealth Regenerative Therapies , located in ... other physically active people a new health option: ... Regardless of age, countless patients suffer from joint and ... such as muscle tears, torn rotator cuff, tennis elbow, ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
... (NYSE: SGP ) today announced that the ... review status to the company,s,New Drug Application (NDA) ... reverse the effects of certain,muscle relaxants, marketed in ... bromide. Muscle relaxants are used as part of,general ...
... The following statement was issued,today by the law firm of ... given that a class action lawsuit was filed in the,United ... on,behalf of all purchasers of the securities of Sanofi-Aventis (NYSE: ... through June 13, 2007,inclusive (the "Class Period")., If you ...
... Dec. 31 Pharmasset, Inc.,(Nasdaq: VRUS ), ... and commercializing novel drugs to treat viral,infections, reported ... 30, 2007. Pharmasset reported a net loss attributable ... share, as compared to a net loss,attributable to ...
Cached Biology Technology:Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 2Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 3Schering-Plough Announces New Drug Application for Sugammadex Assigned Priority Review Status by U.S. FDA 4Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 2Shareholder Class Action Filed Against Sanofi-Aventis by the Law Firm of Schiffrin Barroway Topaz & Kessler, LLP 3Pharmasset Reports Fiscal Year End 2007 Financial Results 2Pharmasset Reports Fiscal Year End 2007 Financial Results 3Pharmasset Reports Fiscal Year End 2007 Financial Results 4Pharmasset Reports Fiscal Year End 2007 Financial Results 5Pharmasset Reports Fiscal Year End 2007 Financial Results 6Pharmasset Reports Fiscal Year End 2007 Financial Results 7Pharmasset Reports Fiscal Year End 2007 Financial Results 8Pharmasset Reports Fiscal Year End 2007 Financial Results 9
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... examples of how wildlife loss leads to conflict among ... Wildlife Conservation Society (WCS) Health & Ecosystems: Analysis ... for an interdisciplinary approach to tackle global biodiversity decline. ... 15% of the world,s people and provides protein for ... should come as no surprise that today,s unprecedented loss ...
(Date:7/24/2014)... - July 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) ... long-term, randomized, active control Phase 3 study of Zerenex ... binder, for the treatment of hyperphosphatemia in patients with ... (PhosphatE binding and iRon delivery with FErric CiTrate in ... of the American Society of Nephrology ( JASN ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... identified several proteins in mice that might act as ... first step to finding a more reliable way to ... and teenagers use illegally to boost muscle and reduce ... in San Francisco today, scientists John Kopchick and Juan ...
... For those patients who receive the nearly 40 ... deficiency, a new oral option may soon exist. ... B12 deficiency can lead to a wide spectrum of ... Vitamin B12 deficiency is a significant health issue. Nearly ...
... ADHD-associated version of the human gene DRD4 is linked ... malnourishment in their settled cousins, according to new research ... University of Wisconsin-Milwaukee (UWM). A study by UWM ... Boston University and UNLV shows that a particular version ...
Cached Biology News:Scientists find potential protein biomarkers for growth hormone 2New technology may prevent vitamin B12 deficient seniors and vegetarians from needing injections 2Did the gene for ADHD help our nomadic ancestors? 2
... designed for two-dimensional electrophoresis (2D) and ... in this marker have been selected ... a 2D gel. The pI range ... Mol wt: 17,000-89,000 Physical Form: ...
... to test the crossreactivity of an antibody ... commonly used as blocking reagents or antigen ... different protein preparations on a nitrocellulose membrane. ... specificity, QC of purified antibodies, selection of ...
... is based on PI's experience in high-resolution ... a decade. PI Hexapods were originally used ... adjustments over wide ranges in small step ... freedom with 3 m minimum incremental motion ...
... can provide custom microplate coating using advanced automated high throughput ... plate formats. We can also accommodate virtually any lot size ... L):, , 8 and ... microplate, 384 well microplate, ...
Biology Products: